Story at a glance
- Pfizer is testing its coronavirus vaccine in different child age groups.
- It's availability for children will depend upon the trial results and FDA approval.
- The revelations came from Pfizer’s CEO during its quarterly earnings call.
The trial results of the Pfizer vaccine’s effectiveness in children ages 2 to 11 should be available by September, according to Pfizer CEO Albert Bourla.
The revelation came Tuesday during Pfizer's quarterly earnings call. Bourla said Pfizer should have data on its effect for 2 to 5-year-olds and 5 to 11-year-olds to submit to the Food and Drug Administration (FDA) at that time.
The data for 6-month-old to 2-year-old children isn’t expected to be available until November.
When children can be vaccinated will depend on the trial results and when the FDA gives Pfizer approval for its use.
On March 31, Pfizer announced that its coronavirus vaccine “demonstrated 100% efficacy” and was "well-tolerated" in 12 to 15-year-olds. Pfizer expects to receive FDA authorization to use the vaccines on that age group next week.
Pfizer's coronavirus vaccine is currently available in the United States for individuals 16 years and older. More than 53 million people in the U.S. have been fully vaccinated with the two-dose Pfizer shot, according to the Centers for Disease Control and Prevention.
BREAKING NEWS ON THE CORONAVIRUS PANDEMIC